Our results show that the response to PD-1 mAb + CX3CR1 immunotherapy is characterized by a remodeling of the myeloid compartments in the tumor with the combination treatment skewing the myeloid populations towards fewer MDSC and more mature macrophages. Here, CX3CR1 is linked to neoplasm.